Boundless Bio Jumps 85% To $2.75 On $230M Merger With Serapha Bio
BOLD•Boundless Bio shares hit a 52-week high of $2.75 following agreement to merge with private Serapha Bio in an all-stock deal securing $230 million in funding. The combined company will advance clinical-stage base-editing treatments, including SERP-01 for severe Alpha-1 Antitrypsin Deficiency.
1. Merger Agreement and Stock Reaction
Boundless Bio's all-stock merger with Serapha Bio led its share price to climb 85% to $2.75, marking a 52-week high. Under the terms, Serapha Bio shareholders receive equity in the combined entity.
2. Clinical Pipeline Focus
The merged company will advance clinical-stage base-editing programs, notably SERP-01 targeting the genetic mutation behind severe Alpha-1 Antitrypsin Deficiency. Management expects this focus to strengthen its position in the gene-editing sector.
3. Funding and Strategic Impact
The merger secures $230 million in funding from healthcare investors to support research and trials, providing balance sheet resilience for drug development. Investors view the transaction as a transformative step that enhances Boundless Bio's capacity to accelerate its pipeline.
